TLX Stock Analysis: Buy, Sell, or Hold?
TLX - Telix Pharmaceuticals Limited American Depositary Shares
$10.21
0.21 (2.10%)
▲
5d:
+7.02%
30d:
-0.58%
90d:
+11.83%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jun 25, 2026
TODAY
Get Alerted When TLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TLX shows positive signals but monitor for confirmation. Market pricing in 6.1% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: TLX shows positive signals but monitor for confirmation. Market pricing in 6.1% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$16.25
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.09
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TLX is currently trading at $10.21, which is considered extended relative to its 30-day fair value range of $9.27 to $10.11. From a valuation perspective, the stock is trading at a premium (Forward PE: 30.6) compared to its historical average (25.6). At these levels, the market is pricing in 6.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is approaching resistance at $10.47. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TLX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.51 (+100.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is approaching resistance at $10.47. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TLX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.51 (+100.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.27 -
$10.11
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.0%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 100.9% below Wall St target ($20.51)
- NEUTRAL: Trading at premium valuation - market expects 6.1% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$9.27 -
$10.11
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.23
Resistance Level
$10.47
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.59
Wall Street Target
$20.51
(+100.9%)
Revenue Growth (YoY)
49.3%
Profit Margin
-0.9%
Valuation Premium vs History
+6.1% premium
PE vs Historical
30.6 vs 25.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.1%
(market-implied from PE analysis)
1-Year Target
$10.83
(+6%)
2-Year Target
$11.49
(+13%)
3-Year Target
$12.19
(+19%)
3-Yr Target (if PE normalizes)
(PE: 31→26)
PE COMPRESSION
$10.21
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 30.6, Growth: 153.8%)
$34.46
(+238%)
Base:
(SPY PE: 21.8, Growth: 153.8%)
$24.54
(+140%)
Bear:
(PE: 18.5, Growth: 153.8%)
$20.86
(+104%)
Share & Embed Analysis
Last updated: June 23, 2026 11:42 PM ET
Data refreshes hourly during market hours. Next update: 12:42 AM
Data refreshes hourly during market hours. Next update: 12:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |
